Active substance |
tucatinib (ONT-380) |
Holder |
Seagen |
Status |
Running |
Indication |
in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2 positive locally advanced or metastatic breast cancer who have received at least 2 prior anti HER2 treatment regimens. |
Public documents |
|
Last update |
18/08/2023 |
Tukysa®
Last updated on 13/02/2024